Revuforj (revumenib) - Syndax Pharma
Revumenib: "Clinical outcomes of Aza/Ven/Rev"; Acute myeloid leukemia (Syndax) - Dec 9, 2024 - ASH 2024: "Overall Response rate = 100% in 37 evaluable patients" 
P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology
https://ir.syndax.com/static-files/c2d8e077-f9ec-412a-bc40-5c0a16170761
 
Dec 9, 2024
 
 
59e407fd-ceba-45b3-9eca-79e9cae0deb3.png

b35f158c-1692-478a-ada2-9a89824754c5.png

cf97a401-8239-4f54-92ce-20bfe429d32d.png